Literature DB >> 19601723

Population pharmacokinetic and pharmacodynamic analysis in allergic diseases.

Mark Lovern1, Maria-Laura Sargentini-Maier, Christian Otoul, Jean-Baptiste Watelet.   

Abstract

In this chapter, we introduce the concepts and methodologies of population analysis as applied to analyzing pharmacokinetic and pharmacodynamic data. One of the key determining characteristics of the population approach is that through it, one seeks not only to characterize deterministic trends in the data, but also to identify and estimate the magnitudes of the important sources of variability within the data. The first section of this chapter provides an introduction to the primary concepts of, and motivation for, population modeling by way of a hypothetical case study. Then, the various methodologies that have been employed throughout the history of population analysis are described in further detail. Of these, the most commonly employed today is nonlinear mixed-effects (NLME) modeling. Finally, notable examples of the application of population PK and PK/PD modeling to treatments for allergies and asthma are discussed. Population PK models have frequently been used to extrapolate exposures to special populations, such as pediatrics, as well as to optimize treatment regimens and trial designs for these populations. Population PK/PD models have most frequently been applied to analyzing and interpreting data from wheal and flare trials, but are also becoming increasingly important in the analysis of PD data from monoclonal antibodies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19601723     DOI: 10.1080/10837450902891543

Source DB:  PubMed          Journal:  Drug Metab Rev        ISSN: 0360-2532            Impact factor:   4.518


  2 in total

Review 1.  Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling?

Authors:  Alexandre Duong; Chantale Simard; Yi Le Wang; David Williamson; Amélie Marsot
Journal:  Antibiotics (Basel)       Date:  2021-04-29

2.  Exposure-Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection.

Authors:  Mohamed-Eslam F Mohamed; Ben Klünder; Heidi S Camp; Ahmed A Othman
Journal:  Clin Pharmacol Ther       Date:  2019-08-23       Impact factor: 6.875

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.